Thumb Ossification Composite Index (TOCI) to Predict Skeletal Maturity and Curve Progression in AIS
Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 4, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method called the Thumb Ossification Classification Index (TOCI) to help predict how much a teenager's scoliosis (curvature of the spine) might progress as they grow. Understanding a patient's skeletal maturity, or how developed their bones are, is crucial for deciding the best treatment options, like whether a brace is needed. The TOCI focuses on measuring specific bones in the thumb to give a clearer picture of a patient's growth stage, which could be more practical and quicker to use than current methods.
To participate in this trial, candidates must be male or female teenagers who have been diagnosed with idiopathic scoliosis and have not yet started menstruating. They should not have any neurological issues or abnormal growth patterns. Participants will have their thumb bone measurements taken as part of the study. This new approach aims to make it easier for doctors to assess skeletal maturity and manage scoliosis effectively. If successful, the TOCI may also be applied to other patients, not just those with scoliosis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female
- • Pre-menarche
- • Confirmed diagnosis of idiopathic scoliosis
- • No evidence of neurological abnormality
- • No abnormalities of maturation
- • Risser sign of zero in spinal radiograph and open physis in hand radiograph
- Exclusion Criteria:
- • Patients with diagnosis of non-idiopathic scoliosis, e.g. congenital, neuromuscular , syndromal cause of scoliosis
- • Patients with maturation abnormality (either precocious puberty or developmental delay)
- • Abnormalities of the head or neck that would change height measurements
- • Previous history of spinal fusion operation performed
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sha Tin, , Hong Kong
Patients applied
Trial Officials
Alec Lik-Hang Hung, Dr.
Principal Investigator
Department of Orthopaedics and Traumatology, Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials